SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    F. Peyvandi, J. Oldenburg, K. D. Friedman, A critical appraisal of one-stage and chromogenic assays of factor VIII activity, Journal of Thrombosis and Haemostasis, 2016, 14, 2
  2. 2
    S. Kitchen, H. Beckmann, Y. Katterle, S. Bruns, D. Tseneklidou-Stoeter, M. Maas Enriquez, BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study, Haemophilia, 2016, 22, 2
  3. 3
    E. Berntorp, C. Negrier, P. Gozzi, P-M. Blaas, S. Lethagen, Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc, Haemophilia, 2016, 22, 2
  4. 4
    P. Mathew, H. Dinter, N. Church, T. J. Humphries, R. Kulkarni, Inhibitors in haemophilia A: a perspective on clotting factor products as a potential contributing factor, Haemophilia, 2016, 22, 2
  5. 5
    Rajiv K. Pruthi, Laboratory monitoring of new hemostatic agents for hemophilia, Seminars in Hematology, 2016, 53, 1, 28

    CrossRef

  6. 6
    J. N. Mahlangu, M. Ragni, N. Gupta, S. Rangarajan, R. Klamroth, J. Oldenburg, K. Nogami, G. Young, L. M. Cristiano, Y. Dong, G. Allen, G. F. Pierce, B. Robinson, Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A, Thrombosis and Haemostasis, 2016, 116, 1

    CrossRef

  7. 7
    N. K. Jha, S. A. Shestopal, M. J. Gourley, S. A. Woodle, Y. Liang, A. G. Sarafanov, M. Weinstein, M. V. Ovanesov, Optimization of the thrombin generation test components to measure potency of factor VIII concentrates, Haemophilia, 2016, 22, 2
  8. 8
    Jennifer A. Dumont, Kenneth S. Loveday, David R. Light, Glenn F. Pierce, Haiyan Jiang, Evaluation of the toxicology and pharmacokinetics of recombinant factor VIII Fc fusion protein in animals, Thrombosis Research, 2015, 136, 6, 1266

    CrossRef

  9. 9
    M. H. Sørensen, S. Andersen, M. Ezban, Factor IX-deficient plasma spiked with N9-GP behaves similarly to N9-GP post-administration clinical samples in N9-GP ELISA and FIX activity assays, Haemophilia, 2015, 21, 6
  10. You have free access to this content10
    J. S. Powell, Longer-acting clotting factor concentrates for hemophilia, Journal of Thrombosis and Haemostasis, 2015, 13,
  11. You have free access to this content11
    Cedric Hermans, Gerry Dolan, Ian Jennings, Jerzy Windyga, Sébastien Lobet, E. Carlos Rodríguez-Merchán, Matteo Nicola Dario Di Minno, Víctor Jiménez-Yuste, Brian O'Mahony, Managing Haemophilia for Life: 5th Haemophilia Global Summit, European Journal of Haematology, 2015, 95,
  12. You have free access to this content12
    J. Dodt, A. R. Hubbard, S. J. Wicks, E. Gray, B. Neugebauer, E. Charton, G. Silvester, Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators, Haemophilia, 2015, 21, 4
  13. 13
    Danielle Nance, George M. Rodgers, Switching haemophilia products and inhibitor risk: a United States' perspective, European Journal of Haematology, 2015, 94, 4
  14. 14
    J. S. Powell, Lasting power of new clotting proteins, Hematology, 2014, 2014, 1, 355

    CrossRef

  15. You have free access to this content15
    J. Oldenburg, T. Albert, Novel products for haemostasis – current status, Haemophilia, 2014, 20,